Late term tolerance in head neck cancer patients irradiated in the IMRT era by Rohrdorf, T et al.
Title Late term tolerance in head neck cancer patients irradiated inthe IMRT era
Author(s)
Studer, G; Linsenmeier, C; Riesterer, O; Najafi, Y; Brown, M;
Yousefi, B; Bredell, M; Huber, G; Schmid, S; Studer, S; Zwahlen,
RA; Rohrdorf, T; Glanzmann, C
Citation Radiation Oncology, 2013, v. 8, article no. 259
Issued Date 2013
URL http://hdl.handle.net/10722/202458
Rights Radiation Oncology. Copyright © BioMed Central Ltd.
Studer et al. Radiation Oncology 2013, 8:259
http://www.ro-journal.com/content/8/1/259RESEARCH Open AccessLate term tolerance in head neck cancer patients
irradiated in the IMRT era
Gabriela Studer1*, Claudia Linsenmeier1, Oliver Riesterer1, Yousef Najafi1, Michelle Brown1, Bita Yousefi1,
Marius Bredell2, Gerhard Huber3, Stephan Schmid4, Stephan Studer2, Roger Zwahlen5, Tamara Rordorf6
and Christoph Glanzmann1Abstract
Background: The aim was to quantify severe transient and persisting late term effects in our single institution head
neck cancer (HNC) cohort treated with curatively intended intensity modulated radiation therapy (IMRT). Hypothesis
was if a 2-year follow up (FU) is sufficient to estimate the long term tolerance in HNC irradiated in the IMRT era.
Methods: Between 01/2002-8/2012, 707/1211 (58%) consecutively treated IMRT patients met the inclusion criteria
of a FU time >12 months and loco-regional disease control (LRC). 45% presented with loco-regionally advanced
disease; 55% were referred for curative definitive IMRT (66 Gy-72 Gy in 30–35 fractions), 45% underwent postoperative
IMRT (60-66 Gy in 30–33 fractions). Systemic concomitant therapy was administered in 85%. Highly consistent treatment
procedures were performed with respect to contouring processes, dose constraints, radiation schedules, and the use of
systemic therapy. Grade 3/4 late term effects were prospectively assessed and analyzed with respect to subgroups at
particular risk for specific late effects.
Results: Mean/median FU of the cohort was 41/35 months (15–124). 13% of the patients (92/707) experienced any
grade 3/4 late effects (101 events in 92/707 patients), 81% in the first 12 months after radiation. 4% of all developed
persisting late grade 3/4 effects (25 events in 25/707 patients).
Conclusions: IMRT led to a high late term tolerance in loco-regionally disease free HNC patients. The onset of any G3/4
effects showed a plateau at 2 years. The question of the cervical vessel tolerance in disease free long time survivors is
still open and currently under evaluation at our institution.
Keywords: Persistent late term effects, Late term tolerance, IMRT and late term effects, Grade 3/4 late effects, IMRT toleranceBackground
Intensity modulated radiation (IMRT) techniques are
expected to improve the therapeutic index for head
neck cancer (HNC) by limiting the dose to critical organs
and possibly increasing loco-regional tumor control. The
benefit of normal tissue sparing achievable with IMRT
with resulting lower rates of late term effects in HNC
survivors is broadly recognized. Data on successful parotid
gland sparing, reduction of radio-osteonecrosis (RON) and
dysphagia are published [1-7]. The probability of specific
late effects depends on the exposed tissue and on the dose,
and sometimes on the chemotherapy.* Correspondence: gabriela.studer@usz.ch
1Department of Radiation Oncology, University Hospital Zurich, Raemistrasse
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reproduction in any medium, provided the orAim of this prospectively assessed single center data
analysis was to evaluate transient and persisting IMRT
late term effects related to subgroups at risk. Hypothesis
was if a 2-year follow up (FU) is sufficient to estimate
the long term tolerance in HNC patients irradiated in
the IMRT era.Methods
Patients
Between 01/2002-8/2012, 1211 HNC patients were con-
secutively treated with IMRT (or volumetric modulated
arc therapy, VMAT) at our department. 707/1211 patients
(58%) met the inclusion criteria of a FU time >12 months
and loco-regional disease control (LRC), Table 1. 45%
presented with advanced disease (T3/4 and/or N2c/N3),
55% were referred for curative definitive IMRT (66 Gy-Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and tumor characteristic
Parameters LRC, >12mo FU
N patients 707
Gender (f: m) 25%:75%
Mean age (range) 62 (39-91) years
Mean/Median FU (range) 41/35 (15-124) months
Diagnosis
Unknown 19 (3%)
Central oropharynx 96 (14%)
Lateral oropharynx 149 (21%)
Hypopharynx 69 (10%)
Oral cavity 111 (16%)
Nasopharynx 51 (7%)
Larynx 90 (13%)
Sinonasal 40 (5%)
Parotid gland 36 (5%)
Skin 33 (5%)
Nasal 10 (1%)
Others 3 (3%)
Treatment (dose)
Primary IMRT (66-72 Gy, 2.0-2.2 Gy/f) 55% (n=388)
Postoperative IMRT (60-66 Gy, 2.0 Gy/f) 45% (n=319)
T
1 17%
2 34%
3 20%
4 26%
Unknown 3%
N stage
Recurrence 2%
NO 32%
N1-2b 45%
N2c 17%
N3 4%
Total gross tumor volume (n=388)
Mean (range) 62 cc (1-217)
1-15 cc 115
16-70 cc 202
71-130 cc 63
>130 cc 8
Conc. systemic therapy
None 15%
Cisplatin only 62%
Cetuximab only 16%
Cisplatin switched to Cetuximab 7%
Induction chemotherapy 3%
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ative radiation (60-66 Gy, 30–33 daily fractions). Systemic
therapy was administered in 85%. Seven LRC patients
were lost after 4.3-10.4 months of FU (median 5.5); 12/
707 (2%) LRC patients were lost after 12.2-51.6 months
(median 39).
In 26 of the 504 excluded patients with locoregional
disease (1211–707), G3/4 late effects were assessed (5%),
however this information is of limited value as tumor-
related symptoms are not always reliably to disdinguish
from treatment-related effects, survival time in patients
with disease is shorter, FU of patients undergoing pallia-
tive systemic therapy often no longer regularly performed
by ENT and maxillofacial surgery joint clinics.
Although acute toxicity was not focus of this work, the
following characteristics of the study population may be
of some interest: early skin tolerance was obviously
better than in the pre-IMRT era (no quantitative com-
parison data) and has been published elsewhere [8]. The
percentage of patients needing a PEG insertion to support
or replace oral nutrition (46% in the study population)
may serve as a surrogate for acceptable dysphagia and
mucositis. In addition, no patient had to interrupt his
radiation course due to early radiation related side effects.
Methods
Highly consistent treatment procedures were performed
with respect to contouring processes, dose constraints,
radiation schedules, use of systemic therapy. Contours
and treatment plans were always evaluated by the same
two staff radiation oncologists (CG/GS).
Implemented changes as evolved from medical and
technical progress over the study time period of 10 years
were the following: use of cetuximab in patients with
contraindications for cisplatinum (since 04/2006); slight
tumor-volume based dose prescription adaptations imple-
mented in 2007 (100% dose coverage of primary GTV in
cases with tumor volume >15 cc); clinical implementation
of VMAT in 4/2010.
Since 2010, the dose to the brachial plexus has been
kept below Dmax 66 Gy, according to the suggestion in
most RTOG protocols (http://www.rtog.org/CoreLab/
ContouringAtlases/BrachialPlexusContouringAtlas.aspx).
Late normal tissue effects were graded according to the
Radiation Therapy Oncology Group (RTOG)/European
Organization for Research and Treatment of Cancer
(EORTC) radiation morbidity scoring criteria [2].
There are several systems aiming to grade RON. We used
the system proposed by Glanzmann and Graetz [9]:
1 Exposed bone without signs of infection for at least
3 months
2 Exposed bone with signs of infection or sequester,
but not grades 3–5
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satisfactory result
4 RON with persistent problems despite mandibular
resection
5 Death due to RON
The advantage of this classification vs. that of EORTC
(LENT/SOMA) or NCI [10] is its connection to thera-
peutic clinical consequences; nevertheless, grade 2
events mutually correspond in all of the above named
classification systems. Most frequent therapy for G2
was limited surgery (partial decortication or debride-
ment, removal of sequesters); these surgical procedures
are not defined in our grading system, and were counted
as ‘G2-3’.
All but the above mentioned 19 lost patients are in
regular FU; nearly all (99%) are followed at our HN or
maxillofacial surgery joint center clinics at the hospital.
Routine tests included, besides the history, physical exam-
ination and endoscopy of the pharyngeal–laryngeal region.
If these tests showed no evidence of disease, usually no
further tests were done but a computed tomography
scan (CT) or positron emission tomography (PET)–CT
or magnetic resonance imaging at 1 year post-treatment
in the majority of patients.
No specific functional swallowing testing was per-
formed to assess subtle (G1-2) dysphagia; reasons to do
so were: no baseline examinations available; many patients
would have shown mild pathological swallowing findings
of no significant impact on the final post treatment func-
tion; as we focused on high grade late term effects (G3/4)
relevant dysphagia with consecutive swallowing problems
(aspiration, aspiration pneumonia, difficulty swallowing
solid food, weight loss, need of PEG) is supposed to
reliably get communicated by patients themselves and/or
diagnosed in the regular FU program in our joint center
clinics.
Similarly, no specific tests were performed to assess
xerostomia G3/4 but patients’ spontaneous complaints
and/or suggestive interview questions in regular FU visits
including objective clinical assessment of severe oral
mucosal dryness. When we implemented IMRT in the
routine, swallowing dysfunction and xerostomia were
graded in the first 100 IMRT patients using subjective
patient-reported (EORTC head-and-neck 35-item swallow-
ing and aspiration (QLQ-H&N35) quality-of-life (QOL)
questionnaire) and objective observer-assessed instru-
ments. As subjective estimations were well fitting
with objective assessments in routinely clinical FU in-
terviews [4], we did not continue to use the EORTC
subjective estimation questionnaires for assessing clin-
ical FU.
With respect to Lhermittes’ sign, no systematic specific
assessments have been performed, which may likely wouldhave revealed more events; however as this symptome is
known for transient and spontaneous entire healing with-
out any therapy, this is not of clinical consequence.
No case of brachial plexus neuropathy (BPN) with
clinically evident dysfunction (grade >2) was diagnosed
in our cohort (patients with post-IMRT neck dissection
excluded); mild neuropathy (G1/2) may be missed with-
out specific neurological examination.
Radiation therapy
In >90% of the cohort the pre-treatment standard im-
aging modality was PET–CT (mostly with intravenous
contrast agent), + tomography (CT or MRI). Planning
CT images (2 mm slice thickness) were acquired from
the vertex or top of the orbita to the carina with contrast
agent infusion in all eligible patients.
Gross tumor volume (GTV) delineation of all patients
was based on physical examination and endoscopy as
well as on diagnostic preoperative MRI, CT and PET.
Contours and treatment plans were always evaluated by
the same two staff radiation oncologists (CG/GS), in
most cases also by a third staff physician.
Technique: Treatment plans were calculated by the
Varian Treatment Planning System (Eclipse® External Beam
Planning System, Version 7.3.10 and PRO 8.9, AAA 8.9,
Varian Medical Systems).
We used an extended-field SIB-IMRT technique, where
the primary tumor is covered in one phase along with
the regional lymph nodes by a 6MV dynamic MLC
system (Varian Medical Systems, Palo Alto, CA) using
a sliding window technique (or using VMAT, since
04/2010). Patients were immobilized from head to shoul-
ders with commercially available thermoplastic masks in
the supine position.
Target volumes were delineated as follows: GTV included
the gross extent of the primary disease and involved lymph
node metastases, taking clinical and radiological findings
into account; planning target volume 1 (PTV1) was de-
fined by adding a (5–) 10–20 mm margin to the GTV,
dependent on the GTV proximity to critical structures
(tight margins mainly if proximity of the GTV to the
mandible bone, spinal cord or brachial plexus/CNS,
generous margins towards tongue and pharyngeal wall,
or in cases with difficult identification of the GTV, or if
clinical findings not entirely represented in the available
imaging); PTV2 covered areas considered at high risk
for potential microscopic disease; PTV3 included the
clinically negative cervical lymphatic pathways (elective
PTV coverage).
SIB IMRT was performed using the following schedules:
– SIB2.00: Daily dose 2.00 Gy (PTV1)/1.70 Gy
(PTV2)/1.54 Gy (PTV3) to a total dose of 70.00 Gy
(5 fractions/week).
Figure 1 Survival rates of the entire IMRT cohort (OAS: overall
survival; LRC: loco-regional control; DMFS: distant metastases
free survival).
Figure 2 Survival rates of 707 patients assessed for late
term tolerance.
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(PTV2)/1.64 Gy (PTV3) to a total dose of 69.60 Gy
(5 fractions/week).
– SIB2.2: Daily dose 2.2 Gy (PTV1)/2.0 Gy (PTV2)/1.64
Gy (PTV3) to a total dose of 66.0 Gy (5 fractions/week).
The dose was normalized to the mean dose in PTV1.
The prescribed dose encompassed at least 95% of the
PTV. In cases with central nervous system involvement,
Dmax accepted was 2.00 Gy, to a Dmax of 70.0 Gy total
dose (PTV1 = GTV; no margin).
No more than 20% of any PTV received >110% of its
prescribed dose, whilst no more than 1% of any PTV re-
ceived <93% of the prescribed dose. Hundred% of the
prescription dose included the primary GTV in patients
with a primary tumor volume >15 cc (since ∼ 2007).
Our interdisciplinary in-house guidelines recommend
an elective neck dissection in patients with initial nodal
metastasis >3 cm.
Chemotherapy
Cisplatin was given in weekly doses of 40 mg/m2 at
1 day a week. Since 04/2006, cetuximab was used in pa-
tients with contra-indications for concomitant standard cis-
platin chemotherapy (400 mg/m2 loading dose, followed by
250 mg/m2 at 1 day a week).
Follow up
3–6 weeks after completion of IMRT, all patients were
also regularly seen in our joint clinic at the Department
of Head and Neck or Maxillofacial Surgery. Institutional
standards for patient assessment included physical examin-
ation with additional flexible fiber-optic endoscopy approxi-
mately every 2 months in the first year of follow-up, every
3 months in the second to third year and every 6 months
in the fourth to fifth year.
Statistics
Kaplan Meier survival curves were performed using the
statistics program implemented in StatView® (Version
4.5). P values < 0.05 were considered statistically signifi-
cant. Unpaired T test and Mann Whitney U test was used
to calculate the influence of the tumor volume on late
tolerance.
Results
Disease control
823 of 1211 (68%) curatively irradiated HNC patients
were alive with no evidence of disease when last seen;
14% died from disease, 7% died for other than HNC rea-
sons, 11% were alive with disease. Kaplan Meier survival
rates of the 5-year overall survival (OAS, 74%), LRC (68%),
and distant metastasis free survival probability (DMFS,
82%) of the entire IMRTcohort are shown in Figure 1.707/1211 patients (58%) met the study inclusion cri-
teria of a FU time >12 months and loco-regional disease
control (LRC), Table 1. The mean/median FU time of
this LRC study cohort was 41/35 months (range 15–124).
Five-year DMFS (91%) and OAS (88%) Kaplan Meier
curves of these patients are illustrated in Figure 2.
Late term tolerance
The following late term G3-4 effects were diagnosed
(Table 2), Additional file 1: Table S1.
– RON (grade 2–4, [9])
– Mucosal ulcer (other than uncovered bone)
– prolonged (>6 months) need of percutaneous
endoscopic gastrostomy (PEG)
– persisting xerostomia/dryness of the pharynx
– need of post-treatment tracheostomy without tumor
– need of post-treatment laryngectomy without tumor
Table 2 Late term effects related to diagnosis
Parameters RON G2-4 Mucosal ulcer PEG Xerostomia Tracheostomy Laryngectomy Loss of taste Others All events/affected
patients
Diagnosis (n),
% persistent
lat oro (6/149), 1% lat oro (9/149), <1% lat oro (7/149), 0% lat oro (1/149), 0% glottic (1/59), 2% SGL (2/31), 6% lat oro (1/149), <1% lat oro (1/149), 0%
cent oro (5/96), 0% centr oro (3/96), 1% centr oro (8/96), 3% hypo (1/69), 0% hypo (1/69), 1% hypo (1/69), 0% centr oro (3/96), 0%
OCC (10/111), 3% OCC (8/111), 0% OCC (4/111), 1% NPC (3/51), 6% parotid (2/36), 6% OCC (1/111), <1%
hypo (4/69), 0% hypo (5/69), 1% (sino-)nasal (5/50), 5%
NPC (1/51), 0%
All 21/356, 6% G2-4 28/593, 5% 28/606, 5% 5/476, 1% 2/159, 1% 2/159, 1% 4/512, 2% 7/707, 1% 101 events in 92/707
patients, 13%
Persistent G3/4
effects (n)
1% (5) <1% (2) <1% (5) <1% (3) 1% (2) 1% (2) <1% (3) <1% (3) 4% (25 events in
25/707 patients)
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– Lhermittes’ sign
The onset of all late term effects (Figure 3) revealed a
plateau at 2 years; 81% of all G3/4 events were diag-
nosed/symptomatic in the first 12 months post radiation.
Table 2 (see also Additional file 1: Table S1) shows diag-
nosed grade 3/4 effects: 92/707 patients (13%) experi-
enced any late term effects, most of them with transient
character or complete recovery following specific therapy.
In 4% (25/707), persisting grade 3/4 effects were stated,
including:
– two patients with arterial bleeding, one with lethal
exit (GTV mean/max 71.8/75.8 Gy, PTV1 mean/
max 69.7/76.2 Gy; 2.2 cc/6.5 cc of the GTV/PTV
exposed to 74-75 Gy)
– 5 patient with partial mandibulectomy/persisting
problems after RON therapy (Table 3); (doses to the
RON area of the mandible were <70.0 Gy in 3
patients, 72 Gy point dose in one, 70–72.3 Gy to
1.5 cc in one)
– 5/28 patients with PEG dependence >6 months
remained PEG dependent (severe dysphagia +/−
aspirations in 4, in one due to insufficient ability to
keep his body weight by oral nutrition despite of
normal swallowing ability); initially in 46% of all
study patients a PEG was inserted to support or
replace oral nutrition
– 3 NPC patients with persisting G3 xerostomia
(<26 Gy to 62%/36%, 72%/44%, and 48%/52% to right/
left parotid glands)
– 2 disease free patients with tracheostomy inserted
post IMRT due to edema,
– 1 patient with persisting secretion from a fistula
after removal of tracheostoma,
– 2 LRC patients with post IMRT laryngectomy due
to necrosis/edemaFigure 3 Onset of any G3/4 late effects following IMRT.– 3 patients with insufficient taste recovery,
– one LRC patient with persisting mucosal ulcer after
post IMRT biopsy
– one patient with slowly healing oral mucositis
(fibrinous mucosal layers >6 months present after
60 Gy postoperative IMRT + concomitant cisplatin)
– 5 nasal/sinonasal tumor patients with persisting
repetitive nasal crusts and/or surgical nasal
synechiolysis +/− lacrimal duct stenosis stenting
All but 2/25 individuals with persisting late effects
presented with advanced HNC; most with personal his-
tory of relevant co-morbidities in addition to nicotine
and alcohol abuse.
Tumor volume didn’t show to be a statistically significant
predictor for G3/4 late effects in the LRC study group: total
GTV (tGTV) in study patients with any G3/4 effects
compared with patients with no relevant late effects was
mean/median (range) 41/33 (1-132 cc) vs 36/27 (1–217),
p = 0.13). The tGTV was expectedly highly significantly
larger in non-study patients (with local or nodal failure)
as compared with the LRC study cohort: mean/median
(range) 55/43 (1-319 cc) vs 39/28 (1-267 cc), p <0.0001.
Discussion
Limitations of this study
a) Methodical limitation given by the inclusion
criterion of loco-regional disease control: as late
term sequelae cannot properly be assessed in patients
with persistent or recurrent tumor, locoregional
control was a key condition for this evaluation,
however, thereby excluding cases with larger tumors
and advanced stages, which may be prone to more
treatment related late toxicity.
b) The authors are aware of the fact of a still relatively
short FU, baring the potential of further upcoming
late sequels (e.g. vascular changes)
c) during the study time period of 10 years, several
changes due to progresses in medicine and
technology have been clinically implemented, like
the use of cetuximab 2006, slight own data driven
tumor-volume based dose prescription adaptations
implemented in 2007, or clinical implementation of
VMAT in 2010. These innovations may have influenced
treatment tolerance. In addition, since 2010, the dose to
the brachial plexus has been kept below Dmax 66 Gy
according to the suggestion in most RTOG protocols.
Of potential benefit with respect to late tolerance may
be our risk adapted pre-IMRT dental care (DC)
program (activated 2006), which allows to spare
more theeth than after conventional DC [11], and
includes tight supervision and care by our dentists
also in the periods during and post radiation
Table 3 Grade 1-4 RON in 21/356 patients at risk (oropharynx or oral cavity tumors irradiated with >60Gy to the mandible): 5 with grade 3/4 RON, 3/5 following
invasive procedures post-IMRT
RON, initial G RON therapy (n) Outcome(n): G Complications(n) following RON therapy: final G Onset post IMRT months IMRT sequence
G1-2
no therapy, spontaneous healing (2) G0 None: G0 5/21 2 definitive
debridment + antibiotics (4)* ad integrum healing (4/4): G0 None: G0 5/6/12 3 postop, 1 definitive
G2-3 partial decortication (11)** ad integrum healing (10/11)**: G0 pathol. fracture, chronic infection (1/11): G4 3 (0-12) 6 postop, 5 definitive
G3 partial mandibulectomy (4) ad integrum healing (1): G3 pathol. fracture (1/4) ***: G4 6/6/18/28*** 3 postop***, 1 definitive
osteomyelitis (1/4) ***: G4
osteocutaneous fistula (1/4)***: G4
*: 2/4 with several previous reconstructive soft tissue operations, dental implants with consecutive bone fracture, followed by superficial RON.
**: 2/11 RON following tooth extraction post-IMRT, 1/11 operated patient with pre-IMRT wound revisions/soft tissue debridement, 1/11 with RON following pre-IMRT dental care tooth extraction.
***: 3/4 RON following dental implants and/or other reconstructive surgery post-IMRT.
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evaluation but from the very first IMRT patients [4]
is a lack of information. Self-scoring has been
recommended to be assess xerostomia [12]. Main
reason not to focus any longer on this topic in the
own patients were the detailed early investigations
on xerostomia and salivary flow rates after IMRT by
Eisbruchs’ group [13]. Their data fitted very well
with the own clinical observations.
The presented evaluation revealed a low rate of
4% G3/4 persisting late term effects, reflecting the now-
adays expectable level of treatment tolerance. The late
effect rate as diagnosed 2 years post treatment comple-
tion was found representative and was unchanged at
5 years (Figure 3). Findings (Tables 2 and 3) compare
well with published data from other centers on treat-
ment tolerance in the IMRT/VMAT era. The compar-
ability of IMRT late effects with that in published IMRT
series is however somewhat limited due to different
tumor cohorts assessed, different approaches to analyze
and/or grade tolerance parameters (e.g. PEG depend-
ence and/or pharyngeal dryness sometimes included in
dysphagia rates, RON events not always graded, side
effects related or not to subgroups at risk).
Treatment tolerance is clearly better nowadays compared
with conventional pre-IMRT era prospective randomized
trials. Reasons for this improvement are multifactorial; the
main reason is the use of IMRT techniques allowing better
sparing of organs at risk while delivering highly conformal
tumor dose. The RTOG 9003 prospective randomized
landmark trial compared normo-fractionation versus dif-
ferent other fractionation schedules in >1000 patients after
conventional radiation techniques, and found grade >/=3
effects in 26.8-37.2% after a median FU of 23 months [14].
Similarly, the prospective randomized SAKK 10/94 trial
investigated the effect of conventional technique hyper-
fractionated radiotherapy +/− concomitant cisplatin; the
corresponding late effect rate was 111 events in 224
treated patients [15].
One of the important advantages of IMRT in oral cav-
ity and oropharyngeal cancer is the reduced RON risk
(1% G3/4 RON in our ‘patients at risk’ cohort with oral
cavity, lateral or central oropharynx cancer (oral cavity
patients at highest risk (3%)), Table 2). The low RON
rate in HNC patients is characteristic for the IMRT era
and comparable with other published series [1,5,6]. None
of our NPC patients treated with IMRT (n = 67 since
2002) was RON affected. RON rates reported in the SAKK
10/94 trial were 6% [15], in the RTOG 9003 trial 2.3%
after a FU of median 23 months [14]. Comparison of the
RON incidence after conventional radiation techniques
during the period between 1980–1990 with 1990–1998
showed a decrease in the risk to a value of ~5% usingthree-dimensional (non-IMRT) techniques and hyper- or
moderately accelerated fractionation [16].
PEG dependence and/or relevant dysphagia are often
multifactorial (mucosal dryness, muscular dysfunction,
tumor related anatomical defects) and were observed in
hypopharynx, oral cavity or central oropharynx tumor
patients; central oropharynx tumor patients were most
often affected (3%). PEG dependence in oropharynx
cancer patients was also described in a series from
Memorial Sloan Kettering Cancer Centre (6/50) [17]. In
the pre-MRT era, this rate was substantially higher (>20%
permanent xerostomia and dysphagia in both study arms
in the SAKK 10/94 trial [15], 10-15% dysphagia and 6-10%
xerostomia in the RTOG 9003 [14], respectively). The low
rate of persisting xerostomia grade 3 (3/51 NPC patients
(6%), oropharyngeal and oral cavity cancer (<1%)) is in
concordance with meanwhile numerous reports on par-
otid sparing in the IMRT literature [3,7,13]. The prob-
ability of severe xerostomia following radiation remains
dependent on the dose and the anatomic distance of
GTV to parotid glands and/or submandibular glands
and the mucosal area included in PTVs. Considering
the missing self-scoring of our patients, the assessed
rate of G3/4 xerostomia may be somewhat higher.
Mucosal ulceration occurred in 28/593 (5%) patients
with pharyngeal or oral cavity cancer (i.e. in patients with
substantial areas of pharyngeal and/or oral mucosa in-
cluded in the high dose planning target volumes, but in
NPC patients), its location was always at the site of the
former primary where also the boost dose was delivered.
Most mucosal ulcers were painful, and clinically and
radiologically hardly to differ from tumor persistence;
its treatment was usually analgetic and/or antibiotic ther-
apy. Early exclusion of local recurrence by biopsy is rec-
ommended. The onset of mucosal ulcer was diagnosed
0–18 months post IMRT completion (mean/median 5/
3 months), comparable to published results [18]; complete
healing took 1–12 months (mean 3.5).
In order to quantify the subgroup of risk for BPN,
dose distribution plans of the first 100 consecutive
patients out of 226 definitively irradiated patients with
nodal disease have been reviewed: in 19/100 (~20%),
the plexus was in part exposed to >65 Gy. No G3/4
brachial arm plexopathy was diagnosed in extrapo-
lated ~40 patients at risk - in concordance with limited
retrospective data from small HNC cohorts published on
this topic [19].
Brain necrosis was not diagnosed in our NPC/sinonasal
cohort as based on clinical and radiological FU assess-
ments (22 cT4 NPC, 8 cT4 sinonasal cancer patients at
risk). In all cases the dose was kept below 70 Gy delivered
in 2.0 Gy/session to <1 cc brain.
Lhermittes’ sign in HNC is rarely reported, and was di-
agnosed in 4 patients. There was no obvious correlation
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patients, with a maximum dose of 46 Gy). Pak et al. pro-
spectively reported on 73 affected patients and found an
incidence rate of 21% which was related to higher spinal
doses than in asymptomatic patients [20].
With regard to the question of cervico-vascular changes,
no robust dose-volume related data are available so far
but descriptions of vascular changes following conven-
tional radiation from several small series [21].
Conclusion
IMRT led to a high late term tolerance in the subgroup
of loco-regionally disease free HNC patients, with only
4% persisting G3/4 effects. The onset of any G3/4 effects
showed a plateau at 2 years.
The question of the cervical vessel tolerance in disease
free long time survivors is still open and currently under
evaluation at our institution.
Additional file
Additional file 1: Table S1. Late term effects related to diagnosis; red:
persistent effects.
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